Pfizer vs Modern vs J&J

Pfizer Moderna Johnson and Johnson COVID vaccines

Studying in Science of more than 780,000 veterans is the first to compare declining protection rates across all three vaccine types available to most Americans, and to directly report death rates after breakthrough infection.

A new study in the leading journal Science reviewed COVID-19 groundbreaking infections among 780,225 veterans who found that vaccine protection dropped from 87.9% to 48.1% during the 2021 Delta rise in the United States. Researchers from PHI, Veterans Affairs Medical Center and the University of Texas Health Science Center found a dramatic drop in the effectiveness of the Janssen (Johnson and Johnson) vaccine, from 86.4% in March to 13% in September. They also found that vaccination of any type was protective against death among infected individuals.

As COVID-19 breakthrough infections continue to appear in some vaccine recipients and health authorities develop policies around booster vaccinations, national data on COVID-19 vaccine breakthrough infections are insufficient, but there is an urgent need. Now a study from the Public Health Institute, Veterans Affairs Medical Center and the University of Texas Health Science Center is published today in the journal Science analyzed COVID infection by vaccination status among 780,225 veterans.

Researchers found that protection against any COVID-19 infection decreased for all vaccine types, with overall vaccine protection decreasing from 87.9% in February to 48.1% in October 2021.

  • The decrease was greatest for the Janssen (Johnson & Johnson) vaccine, where protection against infection decreased from 86.4% in March to 13% in September.
  • The decline for PfizerBioNTech was from 86.9% to 43.3%
  • The decrease for Moderna was 89.2% to 58%.
Diagram of COVID breakthrough infections

Credit: National Institute of Public Health

While most previous studies have focused on the PfizerBioNTech or Moderna vaccines Science the study is the first to compare protection decreases across the three main vaccine types and the first to show the comparatively dramatic decrease in the effectiveness of the Janssen vaccine. Decline was assessed over the period February 1, 2021 to October 1, 2021, reflecting the emergence and dominance of the Delta variant in the United States. Patterns of breakthrough infection over time were consistent with age, despite rolling vaccine eligibility, implying the Delta variant as the primary determinant of infection.

It is important that any type of vaccination was protective against death among people who became infected. The relative benefit of vaccination for death protection was greater for people under 65 years of age, but was also very strong for people over 65 years of age.

The study showed that the risk of death due to COVID infection was highest in unvaccinated veterans, regardless of age and comorbidities. While some breakthrough infections resulted in death, vaccination remained protective against death in those infected during the Delta climb.

For people under the age of 65, vaccines overall were 81.7% effective against death.

  • Death protection was greatest for the Pfizer vaccine with 84.3%.
  • Modern was the second most effective with 81.5%.
  • Jansen was 73% effective.

For those 65 and older, the overall vaccine effectiveness against death was 71.6%.

  • Modern was 75.5% efficient.
  • Pfizer was 70.1% efficient.
  • Jansen was 52.2% effective.

“Our study provides researchers, policy makers, and others with a strong basis for comparing the long-term efficacy of COVID vaccines and a lens for making informed decisions about primary vaccination, booster shots, and other multiple layers of protection, including masking mandates, social distancing. , testing and other public health interventions to reduce the risk of proliferation, “said Dr. Barbara Cohn of PHI, lead author of the study.” For example, the CDC recommendation for boosters for all Janssen recipients over 18 is supported by our findings. of the decline in vaccine protection and the dominance of the more infectious Delta variant, we call for swift action to promote primary vaccination, boosters and also encourage masking, social distancing and other layers of protection against infection.This is supported by our finding of , that breakthrough infections are not benign but also of the strong evidence fo r that vaccination still protects against death, even for people with breakthrough infections, compared to people who become infected and are not vaccinated. ”

The FDA approved Pfizer boosters for some groups in September and Moderna and Janssen boosters in October, and the CDC has made similar recommendations, including support for a “mix and match” approach that allows people to choose one of the three vaccine boosters, whichever they were given in the first place.

Reference: “SARS-CoV-2 vaccine protection and deaths among U.S. veterans during 2021 “by Barbara A. Cohn, Piera M. Cirillo, Caitlin C. Murphy, Nickilou Y. Krigbaum and Arthur W. Wallace, November 4, 2021, Science.
DOI: 10.1126 / science.abm0620

Give a Comment